BLPH - Bellerophon up 14% as enrollment finishes in trial for fibrotic interstitial lung disease therapy
- Bellerophon Therapeutics ( NASDAQ: BLPH ) is up 14% in after-hours trading on Thursday after the company completed enrollment in a phase 3 study of INOpulse, a pulsatile nitric oxide delivery system, for fibrotic interstitial lung disease.
- The 145-patient trial is designed to measure the change in moderate to vigorous physical activity following treatment.
- Bellerophon expects to report top-line results mid year .
- The company surged earlier this month following a deal with Baylor BioSciences in China .
For further details see:
Bellerophon up 14% as enrollment finishes in trial for fibrotic interstitial lung disease therapy